Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

NantKwest and ImmunityBio to initiate a phase 2 study of immunotherapy for metastatic pancreatic can

pharmaceutical-business-reviewMay 20, 2020

Tag: NantKwest , ImmunityBio , metastatic pancreatic cancer , PD-L1 t-haNK , N-803

PharmaSources Customer Service